Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

ACTIV-2: A Study for Outpatients With COVID-19

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04518410
Recruitment Status : Recruiting
First Posted : August 19, 2020
Last Update Posted : October 20, 2020
Sponsor:
Collaborators:
Eli Lilly and Company
AIDS Clinical Trials Group
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)

Brief Summary:

Drug studies often look at the effect one or two drugs have on a medical condition, and involve one company. There is currently an urgent need for one study to efficiently test multiple drugs from more than one company, in people who have tested positive for COVID-19 but who do not currently need hospitalization. This could help prevent disease progression to more serious symptoms and complications, and spread of COVID-19 in the community.

This study looks at the safety and effectiveness of different drugs in treating COVID-19 in outpatients. Participants in the study will be treated with either a study drug or with placebo.


Condition or disease Intervention/treatment Phase
Coronavirus Covid19 Drug: LY3819253 Drug: Placebo Phase 2 Phase 3

Detailed Description:

This is a master protocol to evaluate the safety and efficacy of multiple investigational agents aimed at modifying the host immune response to SARS-CoV-2 infection, or directly enhancing viral control in order to limit disease progression.

The study is designed to transition from phase 2 to phase 3 in the same trial, with or without a pause in enrollment, depending on the speed of enrollment and interim results. For promising agents with limited availability, a phase 3 evaluation may occur at a later time. Up to two dose levels of the same agent may be assessed. Agents may also enter directly into phase 3 evaluation if sufficient safety and efficacy data are available from outside the trial.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 2000 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Masking Description: Unblinded data will be provided to the Data and Safety Monitoring Board for interim analyses. Unblinded Day 28 data will also be provided to a small group of people from the company who owns the investigational agent, to assist the company in deciding if the agent should move into phase 3 evaluation; or in choosing a dose of their agent to move into phase 3 evaluation.
Primary Purpose: Treatment
Official Title: Adaptive Platform Treatment Trial for Outpatients With COVID-19 (Adapt Out COVID)
Actual Study Start Date : August 19, 2020
Estimated Primary Completion Date : November 2020
Estimated Study Completion Date : February 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: ACTIV-2 Drug
Participants in this study will be randomized to receive ACTIV2 Drug or placebo
Drug: LY3819253
Administered by IV infusion

Placebo Comparator: Placebo
The placebo arm may be pooled across more than one experimental arm if multiple investigational drugs are available to be tested at the same time. If it is not possible to use matching placebo over more than one experimental arm, additional placebo arms will be included in the study
Drug: Placebo
Commercially available 0.9% sodium chloride solution. Administered by IV infusion




Primary Outcome Measures :
  1. Duration of COVID-19 symptoms (Phase 2) [ Time Frame: Up to Day 28 ]
    Symptoms: Fever or feeling feverish; cough, shortness of breath or difficulty breathing at rest or with activity; sore throat; body pain or muscle pain/aches; fatigue; headache, chills, nasal obstruction or congestion; nasal discharge (runny nose); nausea or vomiting; and diarrhea. Each symptom is scored daily by the participant as absent (score 0), mild (1), moderate (2) or severe (3)

  2. Post-treatment presence of SARS-CoV-2 RNA at Day 3 (Phase 2) [ Time Frame: Day 3 ]
    Measured as detectable or undetectable, from site-collected NP (nasopharyngeal) swabs

  3. Post-treatment presence of SARS-CoV-2 RNA at Day 7 (Phase 2) [ Time Frame: Day 7 ]
    Measured as detectable or undetectable, from site-collected NP (nasopharyngeal) swabs

  4. Post-treatment presence of SARS-CoV-2 RNA at Day 14 (Phase 2) [ Time Frame: Day 14 ]
    Measured as detectable or undetectable, from site-collected NP (nasopharyngeal) swabs

  5. Post-treatment presence of SARS-CoV-2 RNA at Day 21 (Phase 2) [ Time Frame: Day 21 ]
    Measured as detectable or undetectable, from site-collected NP (nasopharyngeal) swabs

  6. Post-treatment presence of SARS-CoV-2 RNA at Day 28 (Phase 2) [ Time Frame: Day 28 ]
    Measured as detectable or undetectable, from site-collected NP (nasopharyngeal) swabs

  7. Incidence of new adverse event (AE) ≥ Grade 3 (Phase 2) [ Time Frame: Thru Day 28 ]
  8. Cumulative incidence of death from any cause or hospitalization (Phase 3) [ Time Frame: Thru Day 28 ]
    ≥24 hours of acute care in a hospital or similar acute care facility, including Emergency Rooms or temporary facilities instituted ton address medical needs of those with severe COVID-19

  9. Proportion of participants with new adverse event (AE) ≥ Grade 3 (Phase 3) [ Time Frame: Thru Day 28 ]

Secondary Outcome Measures :
  1. Cumulative incidence of death from any cause or hospitalization (Phase 2) [ Time Frame: Thru Day 28 ]
    ≥24 hours of acute care in a hospital or similar acute care facility, including Emergency Rooms or temporary facilities instituted ton address medical needs of those with severe COVID-19

  2. Duration of COVID-19 symptoms (Phase 3) [ Time Frame: Up to Day 28 ]
    Symptoms: Fever or feeling feverish; cough, shortness of breath or difficulty breathing at rest or with activity; sore throat; body pain or muscle pain/aches; fatigue; headache, chills, nasal obstruction or congestion; nasal discharge (runny nose); nausea or vomiting; and diarrhea. Each symptom is scored daily by the participant as absent (score 0), mild (1), moderate (2) or severe (3)

  3. Presence of SARS-CoV-2 RNA (Phases 2 and 3) [ Time Frame: Thru Day 28 ]
    Measured as detectable or undetectable, from participant-collected nasal swabs

  4. Level of SARS-Cov-2 RNA (Phases 2 and 3) [ Time Frame: Thru Day 28 ]
    Measured from participant-collected nasal swabs

  5. COVID-19 severity ranking (Phases 2 and 3) [ Time Frame: From Day 0 thru Day 28 ]
    Based on symptom severity scores. Symptoms: Fever or feeling feverish; cough, shortness of breath or difficulty breathing at rest or with activity; sore throat; body pain or muscle pain/aches; fatigue; headache, chills, nasal obstruction or congestion; nasal discharge (runny nose); nausea or vomiting; and diarrhea. Each symptom is scored daily by the participant as absent (score 0), mild (1), moderate (2) or severe (3). For participants who are alive at 28 days and not previously hospitalized, the severity ranking will be based on the area under the curve (AUC) of the symptom score associated with COVID-19 disease over time. Participants hospitalized or who die during follow-up through 28 days will be ranked as worse than those alive and never hospitalized as follows (in worsening rank order): alive and not hospitalized at 28 days; hospitalized but alive at 28 days; and died at or before 28 days.

  6. Incidence of ≥1 worsening symptom of COVID-19 (Phases 2 and 3) [ Time Frame: Thru Day 28 ]
    Progression of one or more COVID-19-associated symptoms to a worse status than recorded at study entry, prior to start of investigational product or placebo

  7. Duration of fever (Phases 2 and 3) [ Time Frame: Thru Day 28 ]
    Defined as the last day in the participant's study diary on which a temperature ≥ 38°C (100.4°F) was recorded or a potentially antipyretic drug was taken.

  8. Time to self-report return to usual (pre-COVID-19) health (Phases 2 and 3) [ Time Frame: Thru Day 28 ]
    As recorded in participant's study diary

  9. Cumulative incidence of death from any cause or hospitalization (Phases 2 and 3) [ Time Frame: Day 0 thru Week 24 ]
  10. Oxygen saturation level (Phase 2) [ Time Frame: Thru Day 28 ]
    Measured by pulse oximeter and categorized as <96% versus ≥96%

  11. Level of SARS-CoV-2 RNA from site-collected NP swabs (Phase 2) [ Time Frame: Days 0, 3, 7, 14, 21 and 28 ]
    Measured by AUC and above assay lower limit of quantification

  12. Level of SARS-CoV-2 RNA from saliva (Phase 2) [ Time Frame: Days 0, 3, 7, 14, 21 and 28 ]
    Measured by AUC and above assay lower limit of quantification

  13. Level of SARS-CoV-2 RNA from self-collected nasal swabs (Phase 2) [ Time Frame: Daily at Days 0-14, plus Days 21 and 28 ]
    Measured by AUC and above assay lower limit of quantification

  14. Level of SARS-CoV-2 RNA (Phase 2) [ Time Frame: Days 3, 7, 14, 21 and 28 ]
    From site-collected NP swabs

  15. Post-treatment presence of SARS-CoV-2 RNA in saliva (Phase 2) [ Time Frame: Days 3, 7, 14, 21 and 28 ]
    Measured as detectable or undetectable

  16. Post-treatment level of SARS-CoV-2 RNA (Phase 2) [ Time Frame: Days 3, 7, 14, 21 and 28 ]
    Measured from saliva samples

  17. Incidence of new adverse event (AE) ≥ Grade 3 (Phase 3) [ Time Frame: Thru Week 24 ]
  18. Concentration of investigational agent (Phase 2 - LY3819253) [ Time Frame: Days 0, 14, 28, Week 12, Week 24 ]
    Analyses of plasma samples collected from placebo-treated participants are not planned

  19. Level of anti-drug antibodies (Phase 2 - LY3819253) [ Time Frame: Days 0, 14, 28, Week 12, Week 24 ]
    Analyses of plasma samples collected from placebo-treated participants are not planned

  20. AUC (Phase 2 - LY3819253) [ Time Frame: Days 0, 14, 28, Week 12, Week 24 ]
    Area under the concentration-time curve. Analyses of plasma samples collected from placebo-treated participants are not planned

  21. Total body clearance (CL) (Phase 2 - LY3819253) [ Time Frame: Days 0, 14, 28, Week 12, Week 24 ]
    Analyses of plasma samples collected from placebo-treated participants are not planned

  22. Elimination half-life (Phase 2 - LY3819253) [ Time Frame: Days 0, 14, 28, Week 12, Week 24 ]
    T1/2. Analyses of plasma samples collected from placebo-treated participants are not planned

  23. Cmax (Phase 2 - LY3819253) [ Time Frame: Days 0, 14, 28, Week 12, Week 24 ]
    Maximum plasma concentration of LY3819253. Analyses of samples collected from placebo-treated participants are not planned

  24. Cmin (Phase 2 - LY3819253) [ Time Frame: Days 0, 14, 28, Week 12, Week 24 ]
    Minimum plasma concentration of LY3819253. Analyses of samples collected from placebo-treated participants are not planned



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Signed informed consent.
  • Positive test for COVID-19 up to 7 days before participation in study.
  • Able to begin study treatment no later than 10 days from self-reported onset of COVID-19 related symptom(s):

    • fever or feeling feverish
    • cough
    • shortness of breath or difficulty breathing at rest or when active
    • sore throat
    • body pain or muscle pain/aches
    • fatigue
    • headache
    • chills
    • blocked nose/nasal congestion
    • runny nose
    • loss of taste or smell
    • nausea or vomiting
    • diarrhea
    • temperature ≥ 38°C (100.4°F)
  • One or more of the following signs/symptoms within 48 hours of participating in the study:

    • fever or feeling feverish
    • cough
    • shortness of breath or difficulty breathing at rest or when active
    • sore throat
    • body pain or muscle pain/aches
    • fatigue
    • headache
    • chills
    • blocked nose/nasal congestion
    • runny nose
    • loss of taste or smell
    • nausea or vomiting
    • diarrhea
    • temperature ≥ 38°C (100.4°F)
  • Oxygen levels of ≥92% when resting (measured by study staff within 48 hours of participating in the study), unless participant is receiving long-term supplementary oxygen for an underlying lung condition.
  • Participant must agree not to participate in another clinical trial for the treatment of COVID-19 or SARS-CoV-2 during the study period until hospitalization or 28 days after the start of the study, whichever occurs first.

Exclusion Criteria:

  • History of or current hospitalization for COVID-19.
  • Current need for hospitalization or immediate medical attention.
  • Any use of the following medications up to 30 days before participating in the study:

    • Hydroxychloroquine (except for long-term autoimmune diseases)
    • Chloroquine and/or ivermectin (unless used for parasitic infection)
    • Remdesivir, systemic and inhaled steroids (unless used for long-term conditions)
    • HIV protease inhibitors (unless used long-term for HIV infection)
  • Receipt of plasma from a person who recovered from COVID-19 any time before participating in the study.
  • Receipt of a SARS-CoV-2 vaccine any time before participating in the study.
  • Receipt of other investigational treatments for SARS-CoV-2 any time before participating in the study (not including drugs approved and taken for other conditions/diseases).
  • Receipt of systemic steroids (e.g. prednisone, dexamethasone) or inhaled steroids up to 30 days before participating in the study, unless this is a stable dose for a long-term condition.
  • Known allergy/sensitivity or hypersensitivity to study drug or placebo.
  • Any condition requiring surgery up to 7 days before participating in the study, or that is considered life threatening up to 30 days before participating in the study.

Other investigational drug protocol-defined inclusion/exclusion criteria may apply.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04518410


Locations
Show Show 40 study locations
Sponsors and Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
Eli Lilly and Company
AIDS Clinical Trials Group
Investigators
Layout table for investigator information
Study Chair: David Smith, MD, MAS University of California, San Diego
Additional Information:
Layout table for additonal information
Responsible Party: National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier: NCT04518410    
Other Study ID Numbers: A5401/ACTIV-2
38742 ( Other Identifier: DAIDS-ES )
First Posted: August 19, 2020    Key Record Dates
Last Update Posted: October 20, 2020
Last Verified: October 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
COVID-19
Coronavirus
COVID 19
Coronaviridae Infections
Coronavirus Infections
RNA Virus Infections
Virus Diseases
Nidovirales Infections
SARS-CoV-2
SARS Coronavirus
ACTIV-2
ACTIV2
Additional relevant MeSH terms:
Layout table for MeSH terms
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Virus Diseases